Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions

  • Interventional
  • Not Recruiting
  • NCT01414426
Eligibility Details Visit

Randomized Placebo- Controlled Pilot Study of ZD6474 as a Chemopreventive Agent for Premalignant Lesions of the Head and Neck

This randomized phase II trial studies how well vandetanib works in preventing head and neck cancer in patients with precancerous head and neck lesions. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of vandetanib may keep cancer from forming in patients with premalignant lesions


     I. Determine the effect of ZD6474 (vandetanib) compared to placebo on microvessel density (MVD) from baseline to 3 months in patients at risk for oral squamous cell carcinoma (OSCC) with preneoplastic lesions.


     I. Change in MVD over 6 months. II. Change in putative targets of ZD6474: tissues will be analyzed by immunohistochemistry (IHC) for phosphorylated epidermal growth factor receptor (pEGFR), EGFR, phosphorylated-vascular endothelial growth factor receptor 2 (pVEGFR2), VEGFR2.

     III. Change in proliferative index as measured by Ki-67 IHC. IV. Safety, tolerability, and adherence to ZD6474 for 6 months in patients at risk for OSCC.


     I. Compare OSCC incidence in both study arms (ZD6474 and placebo).

     OUTLINE: Patients are randomized to 1 of 2 treatment arms.

     ARM I: Patients receive vandetanib orally (PO) once daily (QD) for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity.

     ARM II: Patients receive placebo PO QD for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity.

     After completion of study treatment, patients are followed up at 9 and 12 months and then every 6 months for 2 years.


Age Group
18 Years and up

Accepting Healthy Volunteers?

Inclusion Criteria:

         - Histological/cytological confirmation of oral cavity dysplasia and one of three additional criteria:

         - Prior history of OSCC

         - Loss of heterozygosity (LOH) at 3p or 9p

         - Expression by immunohistochemistry (IHC) of budding uninhibited by benzimidazoles 3 (BUB3)/sex determining region Y (SOX4)

         - Provision of informed consent

         - Females of child bearing age must have a negative serum pregnancy test within 7 days of first dose of study drug

         - Patients must not have been taking steroids or are on a stable dose of steroids for at least 14 days before enrollment

         - Patients must have a Karnofsky Performance Score of 70% or above

        Exclusion Criteria:

         - History of malignancy within the last 5 years other than squamous cell carcinoma of the head and neck (SCCHN) and superficial non-melanoma skin cancer; patients with a history of SCCHN must be free of active carcinoma

         - Currently receiving treatment for any malignancy

         - Serum bilirubin > 1.5x the upper limit of reference range (ULRR)

         - Creatinine clearance =< 30 mL/minute (calculated by Cockcroft-Gault formula)

         - Potassium, < 4.0 mmol/L despite supplementation; or above the Common Terminology Criteria for Adverse Events (CTCAE) grade 1 upper limit

         - Magnesium below the normal range despite supplementation, or above the CTCAE grade 1 upper limit

         - Serum calcium above the CTCAE grade 1 upper limit; in cases where the serum calcium is below the normal range, 2 options would be available: 1) the calcium adjusted for albumin is to be obtained and substituted for the measured serum value; exclusion is to then be based on the adjusted for albumin values falling below the normal limit; 2) Determine the ionized calcium levels; if these ionized calcium levels are out of normal range despite supplementation, then the patient must be excluded

         - Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 × ULRR

         - Alkaline phosphatase (ALP) > 2.5 x ULRR

         - Evidence of severe or uncontrolled systemic disease or any concurrent condition which in the Investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol

         - Clinically significant cardiovascular event (e.g. myocardial infarction, superior vena cava syndrome [SVC], New York Heart Association [NYHA] classification of heart disease > 2 within 3 months before entry; or presence of cardiac disease that, in the opinion of the Investigator, increases the risk of ventricular arrhythmia

         - History of arrhythmia (multifocal premature ventricular contractions (PVCs), bigeminy, trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation), which is symptomatic or requires treatment (CTCAE grade 3) or asymptomatic sustained ventricular tachycardia; atrial fibrillation, controlled on medication is not excluded

         - QTc prolongation with other medications that required discontinuation of that medication

         - Congenital long QT syndrome or 1st degree relative with unexplained sudden death under 40 years of age

         - Presence of left bundle branch block (LBBB)

         - QTc with Bazett's correction that is unmeasurable or ≥450 msec on screening electrocardiogram (ECG); (Note: If a subject has a QTc interval >= 450 msec on screening ECG, the screen ECG may be repeated twice [at least 24 hours apart]; the average QTc from the three screening ECGs must be < 450 msec in order for the subject to be eligible for the study)

         - Any concurrent medication with a known risk of inducing Torsades de Pointes, that in the investigator's opinion cannot be discontinued

         - Concomitant medications that are potent inducers (rifampicin, rifabutin, phenytoin, carbamazepine, phenobarbital and St. John's Wort) of Cytochrome P450 3A4 (CYP3A4) function

         - Hypertension not controlled by medical therapy (systolic blood pressure greater than 160 mm mercury (Hg) or diastolic blood pressure greater than 100 mm Hg)

         - Currently active diarrhea that may affect the ability of the patient to absorb the ZD6474 or tolerate diarrhea

         - Women who are currently pregnant or breast-feeding

         - Receipt of any investigational agents within 30 days prior to commencing study treatment

         - Previous enrollment or randomization of treatment in the present study

         - Major surgery within 4 weeks or incompletely healed surgical incision before starting study therapy

         - Involvement in the planning and conduct of the study (applies to both Astra Zeneca staff and staff at the study site)

At a Glance

National Government IDNCT01414426


Lead SponsorUniversity of Chicago

Lead PhysicianAlexander Pearson


18 Years and up
Not Recruiting